Overview

Efficacy and Safety of HB-1 for Panic Disorder

Status:
RECRUITING

Trial end date:
2026-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and efficacy of HB-1, versus placebo and two monotherapies, in male and female adult patients aged 18 to 65 years, inclusive, with Panic Disorder.

Phase:

PHASE2

Details

Lead Sponsor:

Honeybrains Biotech LLC

Treatments:

Dosage Forms
Telmisartan
Verapamil